US Stock Market Closed

Dashboard

DURECT Corp. (DRRX)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

B

Industry Comparison

S

Management & Equity

S

Analyst Opinion

S

Leverage & Liquidity

B

Fundamental Variables

B

Rating Performance

FV Performance

*There is a current rating on the stock that is included in these numbers based on its performance so far

About

DURECT Corp. is a biopharmaceutical company. It engages in the research, development, and manufacturing of pharmaceutical products. The company products include alzet and lactel. Its pipeline includes DUR-928, which focuses on lipid homeostasis, inflammation, and cell survival; and POSIMIR, which is an analgesic product intended to deliver bupivacaine to provide pain relief after surgery. The company was founded by James E. Brown and Felix Theeuwes on February 6, 1998 and is headquartered in Cupertino, CA.

CEO

James E. Brown

Employees

90

Industry

Immunology Biopharmaceuticals

Sector

Healthcare

Headquarters

Cupertino

Exchange

NASDAQ

Summary Stats

Market Cap

1.46B

Revenue

23.3M

Net Income

-31.9M

EPS

-$0.14

Price-to-Earnings

-45.86

Price-to-Book

41.97

Debt-to-Equity

0.97

News

Analyst Ratings

Price targets projected by 6 analysts

High

$7.00

Average

$6.17

Low

$5.00

Ratings calculated by 6 analysts

Buy

6

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q3 2022

Last Earnings

Missed by $0.00

Actual

-$0.10 +-0.0%

Consensus

-0.1

Report Date

Year Ago

-0.04

Year Ago Change %

Down 150%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites